USNA (Usana Health Sciences) Cash-to-Debt : No Debt ⁽¹⁾ (As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Usana Health Sciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Usana Health Sciences's cash to debt ratio for the quarter that ended in Sep. 2024 was No Debt ⁽¹⁾.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Usana Health Sciences could pay off its debt using the cash in hand for the quarter that ended in Sep. 2024.

(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Usana Health Sciences's Cash-to-Debt or its related term are showing as below:

USNA' s Cash-to-Debt Range Over the Past 10 Years
Min: 2.28 Med: No Debt Max: No Debt
Current: 276.43

During the past 13 years, Usana Health Sciences's highest Cash to Debt Ratio was No Debt. The lowest was 2.28. And the median was No Debt.

USNA's Cash-to-Debt is ranked better than
93.75% of 1871 companies
in the Consumer Packaged Goods industry
Industry Median: 0.51 vs USNA: 276.43

Usana Health Sciences Cash-to-Debt Historical Data

The historical data trend for Usana Health Sciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Usana Health Sciences Cash-to-Debt Chart

Usana Health Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

28.22

36.20

33.88

41.85

40.98

Usana Health Sciences Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Cash-to-Debt	Get a 7-Day Free Trial															No Debt	40.98	248.74	No Debt	No Debt

Competitive Comparison of Usana Health Sciences's Cash-to-Debt

For the Packaged Foods subindustry, Usana Health Sciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Usana Health Sciences's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Usana Health Sciences's Cash-to-Debt falls into.

Usana Health Sciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Usana Health Sciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	330.42	/	(8.064	+	0)
	=	40.97

Usana Health Sciences's Cash to Debt Ratio for the quarter that ended in Sep. 2024 is calculated as:

Usana Health Sciences had no debt ⁽¹⁾.

Usana Health Sciences (NYSE:USNA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Usana Health Sciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Usana Health Sciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Usana Health Sciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Usana Health Sciences Inc (NYSE:USNA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

USJ:Germany USJ:Germany

Address

3838 West Parkway Boulevard, Salt Lake City, UT, USA, 84120

Website

http://www.usanahealthsciences.com

Usana Health Sciences Inc is a U.S.-based company that is principally engaged in developing, manufacturing, and selling science-based nutritional and personal-care products. The company operates through direct selling. It owns a number of product lines, such as Essentials, which contains core vitamin and mineral supplements; Optimizers, which includes targeted supplements for individuals' health and nutritional needs; Foods, which consists of low-glycemic meal replacement shakes, snack bars, and other related products; and Sense Beautiful Science, which contains personal-care products related to skin and hair. The company conducts business worldwide, including Asia-Pacific, the Americas, and Europe.

Executives

Gilbert A Fuller	officer: CFO and Executive V.P.	55 WANDERWOOD WAY, SANDY UT 84092
Paul A. Jones	officer: CFO	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
John Turman Fleming	director	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Myron W Wentz	director	3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
G Doug Iiekking	officer: VP of Finance	C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120
Daniel A. Macuga	officer: Chief Communications Officer	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120
Kevin Guest	officer: E.V.P. of Marketing	3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Walter Noot	officer: Chief Information Officer	3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Brent Neidig	officer: CO & Man. Dir. of China	3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120
Robert A Sinnott	officer: Chief Scientific Officer	400 55 WATER STREET, VANCOUVER A1 V6B1A1
David Mulham Mulham	officer: Chief Field Development Office	3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120
Joshua Foukas	officer: Chief Legal Officer	3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120
Peggie Pelosi	director	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84111
Frederic J Winssinger	director	2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018
Xia Ding	director	3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120